Lead Product

The compound in NanoMed's lead product is a proven anti-leukemic agent for the treatment of acute leukemias. Leukemia is a cancer of the bone marrow and blood characterized by the uncontrolled accumulation of immature blood cells.  It is primarily a disease of the elderly, with a median age at diagnosis of 68 years.  Acute leukemia progresses rapidly resulting in accumulation of immature, functionless cells in the marrow and blood; that is, the marrow often can no longer produce enough normal platelets, red blood cells and white blood cells.  NanoMed is developing its lead product for use in remission induction therapy in adult acute myelogenous leukemia (AML) in relapsed, MDR1+, elderly AML patients.  Elderly AML patients are biologically and therapeutically distinct from AML in younger adults, and they are intrinsically resistant to chemotherapy and have inferior outcomes. Many elderly AML patients are not offered and/or refuse standard induction and post-remission therapy. Thus, an efficacious, relatively non-toxic approach would be welcomed by patients and leukemia specialists.